Min Li, Li Longqing, Hu Xin, Zhang Yuqi, Wang Jie, Lu Minxun, Zhou Yong, Zhang Wenli, Luo Yi, Tang Fan, Duan Hong, Tu Chongqi
Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022 Jul 15;36(7):796-803. doi: 10.7507/1002-1892.202203004.
To explore the surgical skills of modified Gibson combined with modified ilioinguinal (MGMII) approach in the treatment of Enneking Ⅱ+Ⅲ pelvic malignant tumors in the three-dimensional (3D) printed customized integrated hemipelvic prosthesis, and to evaluate the convenience and accuracy of the surgical approach and the short-term effectiveness.
Between January 2017 and March 2019, 7 patients with Enneking Ⅱ+Ⅲ pelvic malignant tumors were treated with tumor resection and 3D printed hemipelvic prosthesis replacement via MGMII approach. There were 6 males and 1 female. The age ranged from 23 to 68 years, with an average of 43.7 years. There was 1 chondrosarcoma, 1 Ewing's sarcoma, 1 osteosarcoma, 1 malignant Schwannoma, 2 metastatic renal clear cell carcinoma, and 1 metastatic hepatocellular carcinoma. The Enneking stage of 4 cases of primary malignant tumor was stage ⅡB. The disease duration was 6-12 months, with an average of 9.5 months. The preoperative Harris hip score (HHS) was 82.1±1.4 and the Musculoskeletal Tumor Society (MSTS) score was 21.4±1.1. The tumor size by imaging examination was 5.1-9.1 cm, with an average of 6.9 cm. The operation time, intraoperative blood loss, postoperative blood transfusion volume, and postoperative complications were recorded. Postoperative pathological examination confirmed tumor residue according to R classification criteria. The lower limb length, acetabular height, acetabular eccentricity, abduction angle, and anteversion angle were measured and the bone integration was observed by imaging review. Bilateral abductor muscle strengths were measured, and joint function was evaluated by MSTS score and HHS score.
All operations were successfully completed. The operation time was 210-360 minutes (mean, 280.0 minutes); the intraoperative blood loss was 1 300-2 500 mL (mean, 1 785.7 mL); the postoperative blood transfusion volume was 0-11 U (mean, 6.1 U). Postoperative pathological examination confirmed R0 resection assisted by osteotomy guide plate. All incisions healed by first intention. All patients were followed up 30-48 months (mean, 41.3 months). At last follow-up, the imaging review showed the good osseointegration in all 7 cases. There was no significant difference in the lower limb length, acetabular height, acetabular eccentricity, abduction angle, and anteversion angle between the affected side and the healthy side ( >0.05), all of which met the requirements of anatomical reconstruction. At 3 months after operation, the ratios of muscle strength between the affected side and the healthy side was 68.29%±7.41% at 3 months and 89.86%±2.79% at 12 months, showing a significant difference between the two time points ( =8.242, =0.000). At last follow-up, the MSTS score and HHS score were 27.3±0.8 and 96.6±1.4, respectively, which significantly improved when compared with those before operation ( <0.05). None of the patients had assisted walking at last follow-up. There was no recurrence, death, or complications such as deep infection, dislocation of the prosthesis, or fracture of the prosthesis or screw.
MGMII approach can expose the posterior column of the acetabulum, especially the ischial tubercle, which is helpful to avoid tumor rupture during tumor resection and preserve the muscle functions such as gluteus medius and iliac muscle while ensuring the resection scope.
探讨改良吉布森(Gibson)联合改良髂腹股沟(ilioinguinal)(MGMII)入路在三维(3D)打印定制一体化半骨盆假体治疗EnnekingⅡ+Ⅲ期骨盆恶性肿瘤中的手术技巧,并评估该手术入路的便利性、准确性及短期疗效。
2017年1月至2019年3月,7例EnnekingⅡ+Ⅲ期骨盆恶性肿瘤患者采用MGMII入路行肿瘤切除及3D打印半骨盆假体置换术。其中男性6例,女性1例。年龄23~68岁,平均43.7岁。包括软骨肉瘤1例、尤因肉瘤1例、骨肉瘤1例、恶性神经鞘瘤1例、肾透明细胞癌转移瘤2例、肝细胞癌转移瘤1例。4例原发性恶性肿瘤的Enneking分期为ⅡB期。病程6~12个月,平均9.5个月。术前Harris髋关节评分(HHS)为82.1±1.4,肌肉骨骼肿瘤学会(MSTS)评分为21.4±1.1。影像学检查肿瘤大小为5.1~9.1 cm,平均6.9 cm。记录手术时间、术中出血量、术后输血量及术后并发症。术后病理检查按R分类标准确认肿瘤残留情况。通过影像学复查测量下肢长度、髋臼高度、髋臼偏心距、外展角和前倾角,并观察骨整合情况。测量双侧外展肌力量,采用MSTS评分和HHS评分评估关节功能。
所有手术均顺利完成。手术时间为210~360分钟(平均280.0分钟);术中出血量为1 300~2 500 mL(平均1 785.7 mL);术后输血量为0~11 U(平均6.1 U)。术后病理检查确认在截骨导板辅助下实现R0切除。所有切口均一期愈合。所有患者均获随访30~48个月(平均41.3个月)。末次随访时,影像学复查显示7例患者骨整合良好。患侧与健侧下肢长度、髋臼高度、髋臼偏心距、外展角和前倾角比较,差异均无统计学意义(>0.05),均达到解剖重建要求。术后3个月,患侧与健侧肌肉力量比值为68.29%±7.41%,术后12个月为89.86%±2.79%,两个时间点比较差异有统计学意义(=8.242,=0.000)。末次随访时,MSTS评分和HHS评分分别为27.3±0.8和96.6±1.4,与术前比较均显著提高(<0.05)。末次随访时所有患者均无需辅助行走。无复发、死亡,无深部感染、假体脱位、假体或螺钉断裂等并发症发生。
MGMII入路可显露髋臼后柱,尤其是坐骨结节,有助于避免肿瘤切除过程中肿瘤破裂,在确保切除范围的同时保留臀中肌和髂肌等肌肉功能。